Compare ING Groep NV (ING) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Inovio Pharmaceuticals Inc — how do they compare? ING Groep NV trades at $35.67 (market cap $101.22B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: ING Groep NV is far larger — about 1288.6× Inovio Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ING | INO | |
|---|---|---|
Market Cap | $101.22B | $78.55M |
Sector | Financials | Health |
52-Week High | $35.92 | $2.87 |
52-Week Low | $23.66 | $0.66 |
Dividend Yield | 3.73% | — |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING Groep (ING) trades at $35.61, up 1.05% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $0.79 exceeding expectations. Revenue growth remains stable at $22.9B for 2025, supported by a robust 28.34% net income margin and 13.49% ROE. Recent guidance upgrades and strategic acquisitions in wealth management signal management confidence in future growth prospects.
The outlook remains positive with 62.5% analyst buy ratings and technical indicators supporting further upside. Key risks include negative operating cash flows and European banking sector volatility. The stock's attractive 13.24 P/E ratio and dividend yield provide value appeal, though investors should monitor cash flow trends and interest rate sensitivity.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
